- Home
- BVFL vs CRVS Comparison
BVFL vs CRVS Comparison
Compare BVFL & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BVFL
- CRVS
- Stock Information
- Founded
- BVFL 1873
- CRVS 2014
- Country
- BVFL United States
- CRVS United States
- Employees
- BVFL N/A
- CRVS N/A
- Industry
- BVFL Savings Institutions
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- BVFL Finance
- CRVS Health Care
- Exchange
- BVFL Nasdaq
- CRVS Nasdaq
- Market Cap
- BVFL 150.2M
- CRVS 305.4M
- IPO Year
- BVFL N/A
- CRVS 2016
- Fundamental
- Price
- BVFL $15.85
- CRVS $3.95
- Analyst Decision
- BVFL
- CRVS Strong Buy
- Analyst Count
- BVFL 0
- CRVS 4
- Target Price
- BVFL N/A
- CRVS $15.00
- AVG Volume (30 Days)
- BVFL 110.7K
- CRVS 1.2M
- Earning Date
- BVFL 07-17-2025
- CRVS 08-05-2025
- Dividend Yield
- BVFL N/A
- CRVS N/A
- EPS Growth
- BVFL N/A
- CRVS N/A
- EPS
- BVFL 1.06
- CRVS N/A
- Revenue
- BVFL $38,257,000.00
- CRVS N/A
- Revenue This Year
- BVFL N/A
- CRVS N/A
- Revenue Next Year
- BVFL N/A
- CRVS N/A
- P/E Ratio
- BVFL $14.82
- CRVS N/A
- Revenue Growth
- BVFL 1.89
- CRVS N/A
- 52 Week Low
- BVFL $12.00
- CRVS $1.75
- 52 Week High
- BVFL $18.19
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- BVFL 70.48
- CRVS 50.43
- Support Level
- BVFL $15.13
- CRVS $3.55
- Resistance Level
- BVFL $15.41
- CRVS $4.09
- Average True Range (ATR)
- BVFL 0.48
- CRVS 0.31
- MACD
- BVFL 0.18
- CRVS -0.03
- Stochastic Oscillator
- BVFL 97.30
- CRVS 49.14
About BVFL BV Financial Inc.
BV Financial Inc is a federally-chartered savings and loan holding company engaged in offering traditional financial services to consumers and businesses. The company offers savings, interest checking, money market, personal and business checking, non-interest checking, education savings, small business checking, and business checking and certificates of deposit and IRA certificates of deposit. The Company's sources of revenue are derived from interest and dividends earned on loans and investment securities.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).